Ontology highlight
ABSTRACT:
SUBMITTER: Chiu H
PROVIDER: S-EPMC6594227 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
Chiu Hsiling H Trisal Preeti P Bjorklund Chad C Carrancio Soraya S Toraño Estela G EG Guarinos Carla C Papazoglou Despoina D Hagner Patrick R PR Beldi-Ferchiou Asma A Tarte Karin K Delfau-Larue Marie-Hélène MH Morschhauser Franck F Ramsay Alan G AG Gandhi Anita K AK
British journal of haematology 20190214 2
Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R<sup>2</sup> ) has shown clinical synergy in front-line and relapsed/refractory FL. Here, we show that lenalidomide reactivated dysfunctional T and Natural Killer (NK) cells ex vivo from FL patients by enhancing proliferative capacity and T-helper cell type 1 (Th1) cytokine rele ...[more]